Skip to main content
. Author manuscript; available in PMC: 2015 Sep 11.
Published in final edited form as: Cancer. 2015 Apr 22;121(15):2603–2611. doi: 10.1002/cncr.29398

Table 2.

PSA responses.

PSA
(ng/mL)
Median
(Q1–Q3)		 PSA <0.2
(ng/mL)
N(%)
(95% CI)
 PSA ≤0.01
(ng/mL)
N(%)
(95% CI)
 PSA
decrease
≥50% from
baseline
N(%)
(95% CI)		 PSA
decrease
≥90% from
baseline
N(%)
(95% CI)
At completion of docetaxel (n=38) 0.08
(0.03–0.20)		 28(74%)
(57–87)		 6(16%)
(6–31)		 38(100%)
(91–100)		 34(90%)
(75–97)
At completion of ADT (n=37) 0.01
(0.00–0.02)		 37(100%)
(91–100)		 24(65%)
(48–80)		 37(100%)
(91–100)		 36(97%)
(86–100)
1 year after completion of ADT
  Overall (n=36) 0.31
(0.02–0.88)		 16(44%)
(28–62)		 9(25%)
(12–42)		 31(86%)
(71–95)		 17(47%)
(30–65)
  Testosterone ≥100 ng/dL (n=29) 0.30
(0.03–0.70)		 13(45%)
(26–64)		 6(21%)
(8–40)		 25(86%)
(68–96)		 13(45%)
(26–64)
  Testosterone ≥240 ng/dL (n=17) 0.39
(0.08–0.80)		 5(29%)
(10–56)		 2(12%)
(2–36)		 15(88%)
(64–99)		 5(29%)
(10–56)